CMS (00867) saw its shares rise over 3%. As of press time, the stock was up 3.14%, trading at HKD 14.47, with a turnover of HKD 18.3861 million. Recently, CMS issued an announcement stating that its subsidiary, Demai Pharmaceutical Co., Ltd. ("Demai Pharmaceutical," an innovative pharmaceutical company specializing in dermatological health that is applying for an independent listing on the Main Board of The Stock Exchange of Hong Kong Limited), had received approval from the National Medical Products Administration (NMPA) on January 30, 2026, for the New Drug Application (NDA) of Ruxolitinib Phosphate Cream (for the vitiligo indication). The product is indicated for the treatment of non-segmental vitiligo with facial involvement in patients aged 12 and above, including both children and adults. It is the first and only targeted therapy approved in China for the treatment of vitiligo, addressing a significant unmet clinical need. CICC pointed out that Ruxolitinib Cream is a JAK1/JAK2 inhibitor developed by Incyte and is also the first and only repigmentation therapy approved by the FDA for non-segmental vitiligo. According to the company's announcement, it is estimated that approximately 10.3 million people in China suffer from vitiligo (with 8.2 million having the non-segmental type). Existing treatments like TCS/TCIs have clinical limitations, with long-term use leading to adverse reactions or limited efficacy. The institution believes the domestic approval of Ruxolitinib Cream is expected to fill the gap in targeted therapy for vitiligo and meet an unmet clinical need.